Hemab Therapeutics Inc. Common Stock
COAG | NASDAQ
$41.91
+$0.46 (+1.11%)
Nov 2, 2026, 9:58 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | n/a | n/a |
Cost of Revenue | 75K | n/a |
Gross Profit | -75K | n/a |
Operating Income | -49.69M | -23.61M |
Interest Income | 4.08M | 1.22M |
Pretax Income | -46.73M | -22.68M |
Net Income | -46.84M | -22.69M |
Selling & General & Admin | 9.89M | 4.15M |
Research & Development | 39.8M | 19.46M |
Other Expenses | n/a | n/a |
Operating Expenses | 49.69M | 23.61M |
Interest Expense | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 49.69M | 23.61M |
Income Tax Expense | 109K | 12K |
Shares Outstanding (Basic) | 30.11M | 44.19M |
Shares Outstanding (Diluted) | 30.11M | 44.19M |
EPS (Basic) | -1.31 | -0.51 |
EPS (Diluted) | -1.31 | -0.51 |
EBITDA | -49.55M | -23.54M |
EBIT | -49.69M | -23.61M |
Depreciation & Amortization | 146K | 73K |
Add to Watchlist
Select watchlists to add or remove COAG